There are 3397 resources available
Introduction and scientific background
Presenter: Madelon Maurice
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Webcast
Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0
Presenter: Nathan Cherny
Session: Making essential cancer drugs affordable
Resources:
Slides
Webcast
2359O - Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
Presenter: Arlene Siefker-Radtke
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA68 - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Presenter: David Planchard
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Risk assessment stratification
Presenter: Nadia Harbeck
Session: Unravelling choices for adjuvant endocrine therapy in HR+ early breast cancer
Resources:
Slides
Webcast
Degrading oncogenic transcription factors
Presenter: Nicolas Thomä
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Slides
Webcast
LBA102 - THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment
Presenter: James Catto
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
Presenter: Yi Hu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Activation of innate cells through Treg targeting
Presenter: Sergio Quezada
Session: Advancing strategies for cancer immunotherapy
Resources:
Slides
Webcast
When and when not to operate
Presenter: Jean Yannis Perentes
Session: Open questions in the management of mesothelioma
Resources:
Slides
Webcast